News
UTHR delivered strong phase 3 TETON-2 results for nebulized Tyvaso in IPF, meeting the primary endpoint and unlocking major catalyst potential. Read the full stock analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback